Replies to post #43661 on Ayala Pharmaceuticals Inc (fka ADXS)

[pitching51]

Interesting that the study is still active, but closed recruiting...hmmm

Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)

Good results early?

https://globenewswire.com/news-release/2016/04/18/829641/0/en/Late-Breaking-Data-at-AACR-Annual-Meeting-from-Advaxis-Phase-2-Study-of-AXAL-Highlights-Potential-of-the-Company-s-Lm-Technology-Platform.html

[kyndiloh1]

Dosage from 250 to 500 ml. Rather large change there. That would appear to be very positive as far as safety and tolerance are concerned. Hopefully it will translate into profound effectiveness. glta

[DewDiligence]

Just to be clear: That's an investigator- sponsored trial. ADXS' only involvement is to supply the AXAL.

[Julius_Kelp]

Hi pitching51,

Thanks for sharing. You may find this article, published July 2017, interesting. I admit, a good chunk is over my head, but find the "Conclusions" section validating.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512733/